People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...

Novo Nordisk has launched Wegovy in India, an anti-obesity drug aimed at managing weight and reducing cardiovascular risks.

Sprout Health is an online prescriber of weight loss medications. Currently, the only medication available is a compounded semaglutide injection that’s shipped to patients monthly with no membership ...

Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy ...

VANCOUVER, BC / ACCESS Newswire / June 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE ...

Lifestyle therapy may not be enough to improve outcomes for patients with HF and obesity, but careful risk evaluation and ...

A 68-week phase 3 trial found that coadministered cagrilintide and semaglutide led to significant and clinically meaningful ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has accepted the ...

Semaglutide: A High-Growth Market Segment Semaglutide is a GLP-1 analog that has rapidly become a blockbuster drug for type 2 diabetes and obesity, with growing use in cardiovascular risk reduction.

American Idol star Adam Lambert once explained why he switched from Ozempic to Mounjaro after revealing his drastic weight ...

Despite its success, most current Semaglutide formulations still require weekly injections or large daily oral tablets, which can affect patient adherence. A rapidly dissolving oral thin film promises ...